• FR
  • EN
  • JP
  • News
  • Careers
  • Contact Us
Menu

Oncodesign innovation vector.

Oncodesign
  • About
  • Offerings
  • Innovation model
  • Technologies
  • Investors
 

Investors

  • A Word from the Chairman
    • Business model
    • Kinase inhibitor market
  • Financial calendar
  • Share information
    • Share ID
    • Capital structure
    • Stock price
  • Documentation
    • Press releases
      • Press releases 2021
      • Press releases 2020
      • Press release 2019
      • Press release 2018
      • Press releases 2017
      • Press releases 2016
      • Press releases 2015
      • Press releases 2014
      • Press releases 2013
      • Press releases 2012
      • Press releases 2011
      • Press releases 2010
      • Press releases 2009
      • Press releases 2008
    • Shareholders’ meetings (French)
      • Assemblée générale 2020
      • Assemblée générale 2019
      • Assemblée générale 2018
      • Assemblée générale 2017
      • Assemblée générale 2016
      • Assemblée générale 2015
    • AMF Regulated information (French)
      • Communiqués publiés au titre de l'information permanente
      • Informations financières annuelles
      • Informations semestrielles
      • Nombre total de droits de vote et d'actions composant le capital
      • Informations relatives au contrat de liquidité
      • Descriptif des programmes de rachat d'actions
      • Modalités de mise à disposition des prospectus
      • Autres informations réglementées
    • Letters to Shareholders
  • Sign up for e-alert
  • Investors contacts
  1. Home
  2. Share information
  3. Capital structure

Capital structure

Founded in 1995, Oncodesign is built on a balanced business model.

A genuine entrepreneurial project and a rare case in the biotech sector, Oncodesign's capital is primarily in the hands of its top management, including Dr. Philippe Genne, CEO and founder. Thus, the interests of its management and shareholders remain perfectly aligned.

Actionnariat2018 EN

About Oncodesign
  • Vision
  • Our mission
  • Key figures
  • Management
  • Scientific Advisory Board
  • Where to find us
Offerings
  • Services
  • Partnerships 
  • Licensing
  • Therapeutic areas & Experimental models
Our innovation model
  • Etiology
  • Discovery
  • Experimentation
Our technologies
  • Nanocyclix®
  • T.O.T.
  • PREDICT®
  • Chi-mice®
  • Pharmimage®
  • OncoSNIPE®
Investors
  • A word from the Chairman
  • Financial calendar
  • Shares
  • Documentation
  • Sign up for email alerts
  • Investors contacts
Carreers
  • Our values
  • Job offers/work-study arrangements
  • Internships
  • Spontaneous applications
News
  • Upcoming events
  • Webinars
  • Scientific publications
Contact
  • Contact us
  • Sales team
logo AFSII
logo AAALAC

Personal Data PolicyLegal noticeContact Us

(C) copyright Oncodesign - all right reserved

20 rue Jean Mazen | B.P. 27627 | 21076 Dijon Cedex | France | Tel.+33 (0)3.80.78.82.60 | Fax +33 (0)3.80.78.82.61

Newsletter- en

Subscribe to the general newsletter

Invalid Input

Invalid Input

Invalid Input

Subscribe to the Investor Alert

Oncodesign